Embedded Files
According to DelveInsight's evaluation, globally, the Spinal Cord Injury pipeline comprises over 25 key pharmaceutical firms continuously advancing more than 30 Spinal Cord Injury treatment therapies, with analysis of Clinical Trials, Therapeutics, Mechanism of Action, Route of Administration, and Developments conducted by DelveInsight.
"Spinal Cord Injury Pipeline Analysis, 2025" report by DelveInsight outlines comprehensive intelligence into the current clinical development scenario and growth prospects across the Spinal Cord Injury Market.
The Spinal Cord Injury Pipeline analysis encompasses in-depth commercial and clinical evaluation of the pipeline products from the preclinical developmental phase to the marketed phase. The analysis also covers a comprehensive description of the medication, including the mechanism of action of the therapeutic, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Primary Highlights from the Spinal Cord Injury Pipeline Analysis:
Primary Highlights from the Spinal Cord Injury Pipeline Analysis:
Pharmaceutical firms across the globe are diligently advancing toward developing novel Spinal Cord Injury treatment therapies with a considerable amount of success over recent years.
Spinal Cord Injury pharmaceutical firms operating in the treatment market include Athersys, Olatec Therapeutics, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, Kringle Pharma, NervGen Pharma, StemCyte, Inc., among others, are creating therapies for Spinal Cord Injury management.
Emerging Spinal Cord Injury investigational medications in the different phases of clinical trials include Allogeneic stem cell therapy, OLT1177, ALMB0166, AXER-204, FAB117-HC, AST-OPC1, Elezanumab, MT 3921, PMZ-1620, ES 135, KP-100IT, NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, among others, are anticipated to have a significant impact on the Spinal Cord Injury market in the forthcoming years.
In November 2025, Precision Neuroscience's wireless brain-computer interface, engineered to restore function in individuals with paralysis, received support from SCI Ventures, a fund backed by the Christopher & Dana Reeve Foundation and other leading spinal cord injury organizations. The partnership provides Precision with access to SCI Ventures' extensive network of patients, clinicians, and regulatory experts, helping accelerate the development and delivery of the device for individuals with spinal cord injuries and neurological conditions such as ALS and stroke.
In June 2025, Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotech company focused on developing innovative allogeneic ("off-the-shelf") cell therapies for severe neurological and ophthalmic disorders, revealed the addition of new presenters for the 3rd Annual Spinal Cord Injury Investor Symposium (3rd SCIIS). This year's event will be entirely virtual, featuring interactive and on-demand sessions beginning on June 27, 2025.
In March 2025, Cellino and Matricelf (TASE: MTLF) disclosed a partnership aimed at advancing the global biomanufacturing of personalized spinal cord injury therapies. This collaboration integrates Cellino's NebulaTM technology with Matricelf's innovative regenerative medicine approach. By combining Cellino's automated production of induced pluripotent stem cells (iPSCs) with Matricelf's double autologous 3D differentiation process, the partnership seeks to enable scalable and patient-specific regenerative treatments. Cellino's NebulaTM, a proprietary closed-cassette biomanufacturing platform, is specifically designed to generate high-quality iPSCs with exceptional consistency and sterility at a large scale.
In March 2025, NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) revealed the successful completion of a key preclinical investigation supporting its upcoming Investigational New Drug (IND) application. This investigation marks a significant step toward the company's first-in-human trials. The results demonstrated that ExoPTEN treatment, across various dosing regimens, promoted motor function recovery and notably enhanced blood flow at the spinal cord injury site-both critical factors for tissue repair and functional improvement.
In February 2025, Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotech company developing allogeneic cell therapies for severe neurological disorders, disclosed the launch of its DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical investigation. This investigation aims to assess the safety and performance of the Manual Inject Parenchymal Spinal Delivery System (MI PSD System), a new device designed to precisely deliver OPC1, an investigational allogeneic stem cell-based therapy, directly to the spinal cord injury site. OPC1 consists of oligodendrocyte progenitor cells and other related glial cells intended to promote spinal cord repair.
In February 2025, A pilot clinical trial suggests that spinal cord stimulation (SCS) may help reactivate dormant motor neurons and enhance leg muscle strength in individuals with spinal muscular atrophy (SMA). Researchers from the University of Pittsburgh School of Medicine conducted the investigation (NCT05430113), utilizing Medtronic's Vectris SureScan device in three SMA patients. After three months of treatment, all participants showed an improvement of at least 20 meters in the six-minute walk test (6MWT), an indicator used to assess muscle endurance and fatigue.
Spinal Cord Injury Background
Spinal Cord Injury Background
Spinal Cord Injury (SCI) is damage to the spinal cord that results in partial or complete loss of motor, sensory, and autonomic functions below the level of injury. It can occur due to trauma, such as accidents or falls, or from diseases affecting the spinal cord. SCI often leads to paralysis, loss of sensation, and other complications, with the severity depending on the location and extent of the injury. Early medical intervention and rehabilitation are critical for improving outcomes.
Access a Free Sample PDF Report to learn more about Spinal Cord Injury Pipeline Therapeutic Evaluation- https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr
Emerging Spinal Cord Injury Investigational Medications Under Different Phases of Clinical Development Include:
Emerging Spinal Cord Injury Investigational Medications Under Different Phases of Clinical Development Include:
Allogeneic stem cell therapy: Athersys
OLT1177: Olatec Therapeutics
ALMB0166: AlaMab therapeutics
AXER-204: ReNetX Bio
FAB117-HC: Histocell
AST-OPC1: Lineage Cell Therapeutics
Elezanumab: AbbVie
MT 3921: Mitsubishi Tanabe Pharma
PMZ-1620: Pharmazz
ES 135: Eusol Biotech
KP-100IT: Kringle Pharma
NVG-291: NervGen Pharma
Romosozumab: VA Office of Research and Development/Kessler Institute for Rehabilitation
Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc
Spinal Cord Injury Administration Method
Spinal Cord Injury Administration Method
The Spinal Cord Injury pipeline analysis presents therapeutic evaluation of the pipeline medications by Administration Method. Products are classified under various administration routes, such as:
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Spinal Cord Injury Molecular Classification
Spinal Cord Injury Molecular Classification
Spinal Cord Injury products are classified under various molecular categories, such as:
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Spinal Cord Injury Pipeline Therapeutics Evaluation
Spinal Cord Injury Pipeline Therapeutics Evaluation
Spinal Cord Injury Evaluation by Product Category
Spinal Cord Injury By Stage and Product Category
Spinal Cord Injury Evaluation by Administration Method
Spinal Cord Injury By Stage and Administration Method
Spinal Cord Injury Evaluation by Molecular Classification
Spinal Cord Injury by Stage and Molecular Classification
DelveInsight's Spinal Cord Injury Analysis covers approximately 30+ products under different phases of clinical development including:
Late-phase products (Phase III)
Mid-phase products (Phase II)
Early-phase product (Phase I)
Preclinical and Discovery stage candidates
Discontinued & Inactive candidates
Administration Method
Further Spinal Cord Injury product details are provided in the analysis. Access the Spinal Cord Injury pipeline analysis to learn more about the emerging Spinal Cord Injury therapies https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr
Major Pharmaceutical Firms in the Spinal Cord Injury Therapeutics Market Include:
Major Pharmaceutical Firms in the Spinal Cord Injury Therapeutics Market Include:
Key pharmaceutical firms developing therapies for Spinal Cord Injury include NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, among others.
Spinal Cord Injury Pipeline Analysis:
Spinal Cord Injury Pipeline Analysis:
The Spinal Cord Injury pipeline analysis offers intelligence into:
The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Spinal Cord Injury management, including cumulative therapies created by each organization for this indication.
It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Spinal Cord Injury Treatment.
Spinal Cord Injury key pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.
Spinal Cord Injury investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.
Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Spinal Cord Injury market.
The analysis is constructed using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, among others.
Access Sample PDF Report to learn more about Spinal Cord Injury medications and therapies https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr
Spinal Cord Injury Pipeline Market Drivers
Spinal Cord Injury Pipeline Market Drivers
Increase in prevalence of spinal cord injury, increasing awareness about spinal cord injury are some of the important factors that are fueling the Spinal Cord Injury Market.
Spinal Cord Injury Pipeline Market Obstacles
Spinal Cord Injury Pipeline Market Obstacles
However, absence of essential emergency and acute care, lack of importance of a systematic approach towards the management of Spinal cord Injury and other factors are creating obstacles in the Spinal Cord Injury Market growth.
Scope of Spinal Cord Injury Pipeline Drug Intelligence
Scope of Spinal Cord Injury Pipeline Drug Intelligence
Coverage: Global
Key Spinal Cord Injury Pharmaceutical Firms: Athersys, Olatec Therapeutics, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, Kringle Pharma, NervGen Pharma, StemCyte, Inc., among others
Key Spinal Cord Injury Investigational Treatments: Allogeneic stem cell therapy, OLT1177, ALMB0166, AXER-204, FAB117-HC, AST-OPC1, Elezanumab, MT 3921, PMZ-1620, ES 135, KP-100IT, NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, among others
Spinal Cord Injury Therapeutic Evaluation: Spinal Cord Injury current marketed and Spinal Cord Injury emerging therapies
Spinal Cord Injury Market Dynamics: Spinal Cord Injury market drivers and Spinal Cord Injury market obstacles
Request for Sample PDF Report for Spinal Cord Injury Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us:
Contact Us:
Kanishk
Page updated
Report abuse